<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TETRABENAZINE- tetrabenazine tablet </strong><br>Oceanside Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Tetrabenazine Tablets safely and effectively. See full prescribing information for Tetrabenazine Tablets.<br><br>Tetrabenazine Tablets, for Oral use <br>Initial U.S. Approval: 2008</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Underline">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND SUICIDALITY  </span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd> Increases the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Balance risks of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality with the clinical need for control of choreiform movements when considering the use of tetrabenazine tablets. (<a href="#S5.1">5.1</a>)   </dd>
<dt>•</dt>
<dd> Monitor patients for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidality, or unusual changes in behavior. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Inform patients, caregivers and families of the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality and instruct to report behaviors of concern promptly to the treating physician. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Exercise caution when treating patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or prior <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> or ideation. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Tetrabenazine tablets are contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. (<a href="#S4">4</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
</dl>
</div></div>
<div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Underline">WARNING: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND SUICIDALITY  </span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>•</dt>
<dd> Increases the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Balance risks of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality with the clinical need for control of choreiform movements when considering the use of tetrabenazine tablets. (<a href="#S5.1">5.1</a>)   </dd>
<dt>•</dt>
<dd> Monitor patients for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidality, or unusual changes in behavior. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Inform patients, caregivers and families of the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality and instruct to report behaviors of concern promptly to the treating physician. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Exercise caution when treating patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or prior <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> or ideation. (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd> Tetrabenazine tablets are contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. (<a href="#S4">4</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Tetrabenazine tablets are a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with Huntington's disease. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd> Individualization of dose with careful weekly titration is required. The 1<span class="Sup">st</span> week's starting dose is 12.5 mg daily; 2<span class="Sup">nd</span> week, 25 mg (12.5 mg twice daily); then slowly titrate at weekly intervals by 12.5 mg to a tolerated dose that reduces <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>. (<a href="#S2.1">2.1</a>, <a href="#S2.2">2.2</a>)</dd>
<dt>•</dt>
<dd> Doses of 37.5 mg and up to 50 mg per day should be administered in three divided doses per day with the maximum recommended single dose not to exceed 25 mg. (<a href="#S2.2">2.2</a>)</dd>
<dt>•</dt>
<dd> Patients requiring doses above 50 mg per day should be genotyped for the drug metabolizing enzyme CYP2D6 to determine if the patient is a poor metabolizer (PM) or an extensive metabolizer (EM). (<a href="#S2.2">2.2</a>, <a href="#S5.4">5.4</a>)           </dd>
<dt>•</dt>
<dd> The maximum daily dose in PMs is 50 mg with a maximum single dose of 25 mg. (<a href="#S2.2">2.2</a>)</dd>
<dt>•</dt>
<dd> The maximum daily dose in EMs and intermediate metabolizers (IMs) 100 mg with a maximum single dose of 37.5 mg. (<a href="#S2.2">2.2</a>)                            </dd>
<dt>•</dt>
<dd> If serious adverse events occur, titration should be stopped and the dose of tetrabenazine tablets should be reduced.  If the adverse event(s) do not resolve, consider withdrawal of tetrabenazine tablets. (<a href="#S2.2">2.2</a>, <a href="#S5.3">5.2</a>)</dd>
</dl></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>12.5 mg and 25 mg tetrabenazine tablets for oral use (12.5 mg non-scored, 25 mg scored). (<a href="#S3">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients who are actively suicidal, or who have <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> which is untreated or undertreated. (<a href="#S4">4</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>)</dd>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients with impaired hepatic function. (<a href="#S2.5">2.4</a>, <a href="#S4">4</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</dd>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients taking MAOIs or reserpine. (<a href="#S4">4</a>, <a href="#S7.3">7.3</a>, <a href="#S7.4">7.4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd> Periodically reevaluate the benefit of tetrabenazine tablets and potential for adverse effects such as worsening mood, cognition, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and functional capacity. (<a href="#S5.1">5.1</a>)</dd>
<dt>•</dt>
<dd> Do not exceed 50 mg/day and the maximum single dose should not exceed 25 mg if administered in conjunction with a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine) (<a href="#S5.3">5.3</a>, <a href="#S7.1">7.1</a>) </dd>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS). (<a href="#S5.5">5.5</a>, <a href="#S7.6">7.6</a>) Discontinue tetrabenazine tablets if this occurs. (<a href="#S5.5">5.5</a>, <a href="#S7.6">7.6</a>)</dd>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>. Reduce dose or discontinue tetrabenazine tablets if this occurs. (<a href="#S5.6">5.6</a>, <a href="#S5.7">5.7</a>)</dd>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> and <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>. Monitor for <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>. (<a href="#S5.8">5.8</a>)</dd>
<dt>•</dt>
<dd> Sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>. May impair the patient's ability to drive or operate complex machinery. (<a href="#S5.9">5.9</a>)</dd>
<dt>•</dt>
<dd>Alcohol or other sedating drugs can worsen sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. (<a href="#ID_8b52983b-2e7c-4fe7-9438-0d3c29b1d8e8">5.10</a>, <a href="#S7.4">7.4</a>)</dd>
<dt>•</dt>
<dd> QTc prolongation. Do not prescribe in combination with other drugs that prolong QTc.  (<a href="#S5.11">5.11</a>, <a href="#S7.5">7.5</a>, <a href="#S7.6">7.6</a>, <a href="#S12.2">12.2</a>)</dd>
<dt>•</dt>
<dd> Exaggerates <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> when used with drugs that reduce or antagonize dopamine.  Discontinue tetrabenazine tablets if this occurs. (<a href="#S5.15">5.15</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions are (&gt;10% and at least 5% greater than placebo):  Sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#S6">6</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy:  Based on animal data, tetrabenazine may cause fetal harm. (<a href="#S8.1">8.1</a>)</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc"><span class="Emphasis">WARNING:  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND SUICIDALITY</span></a></h1>
<h1><a href="#section-2" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1  General Dosing Considerations  </a></h2>
<h2><a href="#section-3.2" class="toc">2.2  Individualization of Dose</a></h2>
<h2><a href="#section-3.3" class="toc">2.3  CYP2D6 Inhibitors</a></h2>
<h2><a href="#section-3.4" class="toc">2.4  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-3.5" class="toc">2.5 Discontinuation of Treatment</a></h2>
<h2><a href="#section-3.6" class="toc">2.6  Resumption of Treatment</a></h2>
<h1><a href="#section-4" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1  Clinical Worsening and Adverse Effects</a></h2>
<h2><a href="#section-6.2" class="toc">5.2  Dosing of Tetrabenazine Tablets</a></h2>
<h2><a href="#section-6.3" class="toc">5.3 Risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</a></h2>
<h2><a href="#section-6.4" class="toc">5.4  Laboratory Tests</a></h2>
<h2><a href="#section-6.5" class="toc">5.5  Risk of <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</a></h2>
<h2><a href="#section-6.6" class="toc">5.6  Risk of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></a></h2>
<h2><a href="#section-6.7" class="toc">5.7  Risk of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></a></h2>
<h2><a href="#section-6.8" class="toc">5.8  Risk of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></a></h2>
<h2><a href="#section-6.9" class="toc">5.9   Risk of Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-6.10" class="toc">5.10 Interaction with Alcohol</a></h2>
<h2><a href="#section-6.11" class="toc">5.11 Risk of QTc Prolongation</a></h2>
<h2><a href="#section-6.12" class="toc">5.12 Concomitant Use of Neuroleptic Drugs, Reserpine and MAOIs</a></h2>
<h2><a href="#section-6.13" class="toc">5.13 Risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></a></h2>
<h2><a href="#section-6.14" class="toc">5.14 Risk of <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></a></h2>
<h2><a href="#section-6.15" class="toc">5.15  Risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (TD)</a></h2>
<h2><a href="#section-6.16" class="toc">5.16 Use in Patients with Concomitant Illnesses</a></h2>
<h2><a href="#section-6.17" class="toc">5.17   Binding to Melanin-Containing Tissues</a></h2>
<h1><a href="#section-7" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 Commonly Observed Adverse Reactions in Controlled Clinical Trials</a></h2>
<h2><a href="#section-7.2" class="toc">6.1   Clinical Studies Experience</a></h2>
<h2><a href="#section-7.3" class="toc">6.3  Laboratory Tests</a></h2>
<h2><a href="#section-7.4" class="toc">6.4 Vital Signs</a></h2>
<h1><a href="#section-8" class="toc">7   DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1   Strong CYP2D6 Inhibitors</a></h2>
<h2><a href="#section-8.2" class="toc">7.2   Reserpine</a></h2>
<h2><a href="#section-8.3" class="toc">7.3   Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-8.4" class="toc">7.4   Alcohol</a></h2>
<h2><a href="#section-8.5" class="toc">7.5   Drugs that Cause QTc Prolongation</a></h2>
<h2><a href="#section-8.6" class="toc">7.6   Neuroleptic Drugs</a></h2>
<h1><a href="#section-9" class="toc">8    USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1   Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.2   Labor and Delivery</a></h2>
<h2><a href="#section-9.3" class="toc">8.3   Nursing Mothers</a></h2>
<h2><a href="#section-9.4" class="toc">8.4   Pediatric Use</a></h2>
<h2><a href="#section-9.5" class="toc">8.5   Geriatric Use</a></h2>
<h2><a href="#section-9.6" class="toc">8.6   Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></a></h2>
<h2><a href="#section-9.7" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</a></h2>
<h2><a href="#section-9.8" class="toc">8.8 Use in Poor or Extensive CYP2D6 Metabolizers</a></h2>
<h2><a href="#section-9.9" class="toc">8.9 Use in Patients at Risk from QTc Prolongation</a></h2>
<h2><a href="#section-9.10" class="toc">8.10 Use in Patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></a></h2>
<h1><a href="#section-10" class="toc">9   DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-10.1" class="toc">9.1   Controlled Substance Class</a></h2>
<h2><a href="#section-10.2" class="toc">9.2   Abuse</a></h2>
<h1><a href="#section-11" class="toc">10   OVERDOSAGE</a></h1>
<h2><a href="#section-11.1" class="toc">10.1 Human Experience</a></h2>
<h2><a href="#section-11.2" class="toc">10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></a></h2>
<h1><a href="#section-12" class="toc">11   DESCRIPTION</a></h1>
<h1><a href="#section-13" class="toc">12   CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">12.1   Mechanism of Action</a></h2>
<h2><a href="#section-13.2" class="toc">12.2   Pharmacodynamics</a></h2>
<h2><a href="#section-13.3" class="toc">12.3  Pharmacokinetics </a></h2>
<h1><a href="#section-14" class="toc">13   NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-14.1" class="toc">13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-15" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-16.1" class="toc">16.1   How Supplied</a></h2>
<h2><a href="#section-16.2" class="toc">16.2   Storage</a></h2>
<h1><a href="#section-17" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">17.1 Risk of Suicidality</a></h2>
<h2><a href="#section-17.2" class="toc">17.2 Risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-17.3" class="toc">17.3 Dosing of Tetrabenazine Tablets</a></h2>
<h2><a href="#section-17.4" class="toc">17.4 Risk of Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-17.5" class="toc">17.5 Interaction with Alcohol </a></h2>
<h2><a href="#section-17.6" class="toc">17.6 Usage in Pregnancy</a></h2>
<h2><a href="#section-17.7" class="toc">17.7 General Advice</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6ba2a22c-991d-4cf6-b2ec-ee3674a422bd"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Tetrabenazine Tablets </span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING:  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">DEPRESSION</span> AND SUICIDALITY</span></h1>
<p class="First"><span class="Bold">Tetrabenazine tablets can increase the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Anyone considering the use of tetrabenazine tablets must balance the risks of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality with the clinical need for control of choreiform movements. Close observation of patients for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidality, or unusual changes in behavior should accompany therapy. Patients, their caregivers, and families should be informed of the risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. </span></p>
<p><span class="Bold">Particular caution should be exercised in treating patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or prior <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> or ideation, which are increased in frequency in Huntington's disease. Tetrabenazine tablets are contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, and <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-2"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<p class="First">Tetrabenazine tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with Huntington's disease.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-3"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-3.1"></a><p></p>
<h2>2.1  General Dosing Considerations  </h2>
<p class="First">The chronic daily dose of tetrabenazine tablets used to treat <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with Huntington's disease (HD) is determined individually for each patient.  When first prescribed, tetrabenazine tablets therapy should be titrated slowly over several weeks to identify a dose of tetrabenazine tablets that reduces <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> and is tolerated.  Tetrabenazine tablets can be administered without regard to food <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-3.2"></a><p></p>
<h2>2.2  Individualization of Dose</h2>
<p class="First">The dose of tetrabenazine tablets should be individualized.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d01ad3f3-b64f-41e2-a65c-e04768fd65d6"></a><a name="section-3.2.1"></a><p></p>
<p class="First"><span class="Bold">Dosing Recommendations Up to 50 mg per day      </span></p>
<p>The starting dose should be 12.5 mg per day given once in the morning. After one week, the dose should be increased to 25 mg per day given as 12.5 mg twice a day. Tetrabenazine tablets should be titrated up slowly at weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>. If a dose of 37.5 to 50 mg per day is needed, it should be given in a three times a day regimen. The maximum recommended single dose is 25 mg. If adverse events such as <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or sedation occur, titration should be stopped and the dose should be reduced. If the adverse event does not resolve, consideration should be given to withdrawing tetrabenazine tablets treatment or initiating other specific treatment (e.g., antidepressants) <span class="Italics">[see <a href="#_Ref">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b864c86-5da5-4b7f-9bad-072962b41049"></a><a name="section-3.2.2"></a><p></p>
<p class="First"><span class="Bold">Dosing Recommendations Above 50 mg per day          </span></p>
<p>Patients who require doses of tetrabenazine tablets greater than 50 mg per day should be first tested and genotyped to determine if they are poor metabolizers (PMs) or extensive metabolizers (EMs) by their ability to express the drug metabolizing enzyme, CYP2D6. The dose of tetrabenazine tablets should then be individualized accordingly to their status as PMs or EMs <span class="Italics">[see Warnings and Precautions (<a href="#S5.3">5.2</a>, <a href="#S5.4">5.4</a>), <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_609c166a-c43e-416f-a592-ff721293c35f"></a><a name="section-3.2.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Extensive and Intermediate CYP2D6 Metabolizers </span></span></p>
<p>Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of CYP2D6, who need doses of tetrabenazine tablets above 50 mg per day, should be titrated up slowly at weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>. Doses above 50 mg per day should be given in a three times a day regimen. The maximum recommended daily dose is 100 mg and the maximum recommended single dose is 37.5 mg.  If adverse events such as <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or sedation occur, titration should be stopped and the dose should be reduced. If the adverse event does not resolve, consideration should be given to withdrawing tetrabenazine tablets treatment or initiating other specific treatment (e.g., antidepressants) <span class="Italics">[see Warnings and Precautions (<a href="#S5.3">5.2</a>, <a href="#S5.4">5.4</a>), <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0cfbbbcb-2856-4514-bb87-794dcd0d9e09"></a><a name="section-3.2.2.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Poor CYP2D6 Metabolizers</span></span></p>
<p>In PMs, the initial dose and titration is similar to EMs except that the recommended maximum single dose is 25 mg, and the recommended daily dose should not exceed a maximum of 50 mg <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.2)</a>, <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-3.3"></a><p></p>
<h2>2.3  CYP2D6 Inhibitors</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_93ff041a-3327-43f4-a477-7dede75fb063"></a><a name="section-3.3.1"></a><p></p>
<p class="First"><span class="Bold">Strong CYP2D6 Inhibitors </span></p>
<p>Medications that are strong CYP2D6 inhibitors such as quinidine or antidepressants (e.g., fluoxetine, paroxetine) significantly increase the exposure to α-HTBZ and β-HTBZ, therefore, the total dose of tetrabenazine tablets should not exceed a maximum of 50 mg and the maximum single dose should not exceed 25 mg <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>, <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].  </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-3.4"></a><p></p>
<h2>2.4  Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Because the safety and efficacy of the increased exposure to tetrabenazine tablets and other circulating metabolites are unknown, it is not possible to adjust the dosage of tetrabenazine tablets in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to ensure safe use.  Therefore, tetrabenazine tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_9965e8c0-d615-4fef-8291-c19cd0180a12">Warnings and Precautions (5.16)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2b8c66d-d835-447c-880e-c9c519c042c2"></a><a name="section-3.5"></a><p></p>
<h2>2.5 Discontinuation of Treatment</h2>
<p class="First">Treatment with tetrabenazine tablets can be discontinued without tapering.  Re-emergence of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> may occur within 12 to 18 hours after the last dose of tetrabenazine tablets <span class="Italics">[see <a href="#S9.2">Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-3.6"></a><p></p>
<h2>2.6  Resumption of Treatment</h2>
<p class="First">Following treatment interruption of greater than five (5) days, tetrabenazine tablets therapy should be re-titrated when resumed. For short-term treatment interruption of less than five (5) days, treatment can be resumed at the previous maintenance dose without titration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-4"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Tetrabenazine tablets are available in the following strengths and packages:</p>
<p>The 12.5 mg tetrabenazine tablets are white, cylindrical biplanar tablets with beveled edges, non-scored, embossed on one side with "CL" and "12.5."</p>
<p>The 25 mg tetrabenazine tablets are yellowish-buff, cylindrical biplanar tablets with beveled edges, scored, embossed on one side with "CL" and "25."</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-5"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients who are actively suicidal, or in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> <span class="Italics">[see <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>].</span>
</dd>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients with impaired hepatic function <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.4)</a>, <a href="#ID_9965e8c0-d615-4fef-8291-c19cd0180a12">Warnings and Precautions (5.16)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span>
</dd>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI <span class="Italics">[see <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">Warnings and Precautions (5.12)</a> and Drug Interactions (<a href="#S7.2">7.2</a>, <a href="#S7.3">7.3</a>)]. </span>
</dd>
<dt>•</dt>
<dd>Tetrabenazine tablets are contraindicated in patients taking reserpine.  At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets <span class="Italics">[see <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">Warnings and Precautions (5.12)</a> and <a href="#S7.2">Drug Interactions (7.2)</a>]. </span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-6"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-6.1"></a><p></p>
<h2>5.1  Clinical Worsening and Adverse Effects</h2>
<p class="First">Huntington's disease is a progressive disorder characterized by changes in mood, cognition, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and functional capacity over time. In a 12-week controlled trial, tetrabenazine tablets were also shown to cause slight worsening in mood, cognition, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and functional capacity.  Whether these effects persist, resolve, or worsen with continued treatment is unknown. Therefore, proper use of the drug requires attention to all facets of the underlying disease process over time.</p>
<p>Prescribers should periodically re-evaluate the need for tetrabenazine tablets in their patients by assessing the beneficial effect on <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> and possible adverse effects, including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, cognitive decline, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. It may be difficult to distinguish between drug-induced side-effects and progression of the underlying disease; decreasing the dose or stopping the drug may help the clinician distinguish between the two possibilities.  In some patients, underlying <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> itself may improve over time, decreasing the need for tetrabenazine tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-6.2"></a><p></p>
<h2>5.2  Dosing of Tetrabenazine Tablets</h2>
<p class="First">Proper dosing of tetrabenazine tablets involves titration of therapy to determine an individualized dose for each patient.  When first prescribed, tetrabenazine tablets therapy should be titrated slowly over several weeks to allow the identification of a dose that both reduces <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> and is tolerated <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]. </span>Some adverse effects such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> may be dose-dependent and may resolve or lessen with dosage adjustment or specific treatment.  If the adverse effect does not resolve or decrease, consider discontinuing tetrabenazine tablets.  </p>
<p>Doses above 50 mg should not be given without CYP2D6 genotyping patients to determine if they are poor metabolizers <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S5.4">Warnings and Precautions (5.4)</a>, <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7df858eb-c605-4255-ad82-76d29f258a50"></a><a name="section-6.3"></a><p></p>
<h2>5.3 Risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</h2>
<p class="First">Patients with Huntington's disease are at increased risk for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or behaviors (suicidality).  Tetrabenazine tablets increase the risk for suicidality in patients with HD.  All patients treated with tetrabenazine tablets should be observed for new or worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality. If <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality does not resolve, consider discontinuing treatment with tetrabenazine tablets.</p>
<p>In a 12-week, double-blind placebo-controlled study in patients with <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with Huntington's disease, 10 of 54 patients (19%) treated with tetrabenazine tablets were reported to have an adverse event of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> compared to none of the 30 placebo-treated patients.  In two open-label studies (in one study, 29 patients received tetrabenazine tablets for up to 48 weeks; in the second study, 75 patients received tetrabenazine tablets for up to 80 weeks), the rate of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>/worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was 35%. </p>
<p>In all of the HD <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> studies of tetrabenazine tablets (n=187), one patient committed <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, one <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span>, and six had <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>. </p>
<p>Clinicians should be alert to the heightened risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> in patients with Huntington's disease regardless of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> indices. Reported rates of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span> among individuals with Huntington's disease ranged from 3-13% and over 25% of patients attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> at some point in their illness. </p>
<p>Patients, their caregivers, and families should be informed of the risks of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and suicidality associated with tetrabenazine tablets and should be instructed to report behaviors of concern promptly to the treating physician. Patients with HD who express <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> should be evaluated immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-6.4"></a><p></p>
<h2>5.4  Laboratory Tests</h2>
<p class="First">Before prescribing a daily dose of tetrabenazine tablets that is greater than 50 mg per day, patients should be genotyped to determine if they express the drug metabolizing enzyme, CYP2D6.  CYP2D6 testing is necessary to determine whether patients are poor metabolizers (PMs), extensive (EMs) or intermediate metabolizers (IMs) of tetrabenazine tablets.</p>
<p>Patients who are PMs of tetrabenazine tablets will have substantially higher levels of the primary drug metabolites (about 3-fold for α-HTBZ and 9-fold for β-HTBZ) than patients who are EMs.  The dosage should be adjusted according to a patient's CYP2D6 metabolizer status.  In patients who are identified as CYP2D6 PMs, the maximum recommended total daily dose is 50 mg and the maximum recommended single dose is 25 mg <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-6.5"></a><p></p>
<h2>5.5  Risk of <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with tetrabenazine tablets and other drugs that reduce dopaminergic transmission <span class="Italics">[see <a href="#_Ref">Warnings and Precautions (5.12)</a>, <a href="#S7.6">Drug Interactions (7.6)</a>]. </span> Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. The diagnosis of NMS can be complicated; other serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), and untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span> can present with similar signs and symptoms. Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.</p>
<p>The management of NMS should include (1) immediate discontinuation of tetrabenazine tablets and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>Recurrence of NMS has been reported. If treatment with tetrabenazine tablets is needed after recovery from NMS, patients should be monitored for signs of recurrence.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-6.6"></a><p></p>
<h2>5.6  Risk of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></h2>
<p class="First">In a 12-week, double-blind, placebo-controlled study in patients with <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with HD, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> was observed in 10 (19%) of tetrabenazine-treated patients and 0% of placebo-treated patients. In an 80-week open-label study, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> was observed in 20% of tetrabenazine-treated patients. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> was not observed in a 48-week open-label study. Patients receiving tetrabenazine tablets should be monitored for the presence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>. Patients receiving tetrabenazine tablets should also be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, as these may be indicators of developing <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>.  If a patient develops <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, the tetrabenazine tablets dose should be reduced; however, some patients may require discontinuation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-6.7"></a><p></p>
<h2>5.7  Risk of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></h2>
<p class="First">Tetrabenazine tablets can cause <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>. In a 12-week double-blind, placebo-controlled study in patients with <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with HD, symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> (i.e., <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span> and <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>) were observed in 15% of tetrabenazine-treated patients compared to 0% of placebo-treated patients. In 48-week and 80-week open-label studies, symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> were observed in 10% and 3% of tetrabenazine-treated patients, respectively. Because <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span> can develop as part of the underlying disease process in Huntington's disease, it may be difficult to distinguish between this drug-induced side-effect and progression of the underlying disease process. Drug-induced <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> has the potential to cause more functional <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> than untreated <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> for some patients with Huntington's disease.  If a patient develops <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> during treatment with tetrabenazine tablets, dose reduction should be considered; in some patients, discontinuation of therapy may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-6.8"></a><p></p>
<h2>5.8  Risk of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> is a component of HD. However, drugs that reduce dopaminergic transmission have been associated with esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>. <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> may be associated with <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>. In a 12-week, double-blind, placebo-controlled study in patients with <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with HD, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> was observed in 4% of tetrabenazine-treated patients and 3% of placebo-treated patients. In 48-week and 80-week open-label studies, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> was observed in 10% and 8% of tetrabenazine-treated patients, respectively. Some of the cases of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> were associated with <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>. Whether these events were related to treatment is unknown. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-6.9"></a><p></p>
<h2>5.9   Risk of Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Sedation is the most common dose-limiting adverse effect of tetrabenazine tablets. In a 12-week, double-blind, placebo-controlled trial in patients with <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> associated with HD, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> occurred in 17/54 (31%) tetrabenazine-treated patients and in 1 (3%) placebo-treated patient. Sedation was the reason upward titration of tetrabenazine tablets was stopped and/or the dose of tetrabenazine tablets was decreased in 15/54 (28%) patients. In all but one case, decreasing the dose of tetrabenazine tablets resulted in decreased sedation. In 48-week and 80-week open-label studies, sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> occurred in 17% and 57% of tetrabenazine-treated patients, respectively. In some patients, sedation occurred at doses that were lower than recommended doses.</p>
<p>Patients should not perform activities requiring mental alertness to maintain the safety of themselves or others, such as operating a motor vehicle or operating hazardous machinery, until they are on a maintenance dose of tetrabenazine tablets and know how the drug affects them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b52983b-2e7c-4fe7-9438-0d3c29b1d8e8"></a><a name="section-6.10"></a><p></p>
<h2>5.10 Interaction with Alcohol</h2>
<p class="First">Patients should be advised that the concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a> and <a href="#S7.4">Drug Interactions (7.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-6.11"></a><p></p>
<h2>5.11 Risk of QTc Prolongation</h2>
<p class="First">Tetrabenazine tablets causes a small increase (about 8 msec) in the corrected QT (QTc) interval. QT prolongation can lead to development of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> with the risk increasing as the degree of prolongation increases <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a>].</span> The use of tetrabenazine tablets should be avoided in combination with other drugs that are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide), and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval <span class="Italics">[see Drug Interactions (<a href="#S7.5">7.5</a>, <a href="#S7.6">7.6</a>) and <a href="#ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc">Use in Specific Populations (8.9)</a>].</span></p>
<p>Tetrabenazine tablets should also be avoided in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.  Certain circumstances may increase the risk of the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including (1) <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; (2) <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval <span class="Italics">[see <a href="#ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc">Use in Specific Populations (8.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5"></a><a name="section-6.12"></a><p></p>
<h2>5.12 Concomitant Use of Neuroleptic Drugs, Reserpine and MAOIs</h2>
<p class="First"><span class="Bold">Neuroleptic Drugs</span></p>
<p>Patients taking neuroleptic (antipsychotic) drugs (e.g., chlorpromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) were excluded from clinical studies during the tetrabenazine tablets development program.  Adverse reactions associated with tetrabenazine tablets, such as QTc prolongation, NMS, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span>, may be exaggerated by concomitant use of dopamine antagonists <span class="Italics">[see Warnings and Precautions (<a href="#S5.5">5.5</a>, <a href="#S5.11">5.11</a>), Drug Interactions (<a href="#S7.5">7.5</a>, <a href="#S7.6">7.6</a>), and <a href="#ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc">Use in Specific Populations (8.9)</a>].</span></p>
<p><span class="Bold">Reserpine</span></p>
<p>Reserpine binds irreversibly to VMAT2, and the duration of its effect is several days.  The physician should wait for <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> to reemerge before administering tetrabenazine tablets to avoid overdosage and major depletion of serotonin and norepinephrine in the CNS.  At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets.  Tetrabenazine tablets and reserpine should not be used concomitantly <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S7.2">Drug Interactions (7.2)</a>].</span></p>
<p><span class="Bold">Monoamine Oxidase Inhibitors (MAOIs)</span></p>
<p>Tetrabenazine tablets are contraindicated in patients taking MAOIs.  Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S7.3">Drug Interactions (7.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-6.13"></a><p></p>
<h2>5.13 Risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></h2>
<p class="First">Tetrabenazine tablets induced postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> in healthy volunteers receiving single doses of 25 or 50 mg.  One subject had <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and one subject with postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> had documented orthostasis.  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> occurred in 4% of tetrabenazine-treated patients (vs. none on placebo) in the 12-week controlled trial; however, blood pressure was not measured during these events. Monitoring of vital signs on standing should be considered in patients who are vulnerable to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-6.14"></a><p></p>
<h2>5.14 Risk of <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></h2>
<p class="First">Tetrabenazine tablets elevates serum prolactin concentrations in humans. Following administration of 25 mg to healthy volunteers, peak plasma <span class="product-label-link" type="condition" conceptid="4035688" conceptname="Increased prolactin level">prolactin levels increased</span> 4- to 5-fold. Tissue culture experiments indicate that approximately one third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if tetrabenazine tablets are being considered for a patient with previously detected breast cancer. Although <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> can be caused by elevated serum prolactin concentrations, the clinical significance of elevated serum prolactin concentrations for most patients is unknown. Chronic increase in serum prolactin levels (although not evaluated in the tetrabenazine tablets development program) has been associated with low levels of estrogen and increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. If there is a clinical suspicion of symptomatic <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, appropriate laboratory testing should be done and consideration should be given to discontinuation of tetrabenazine tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-6.15"></a><p></p>
<h2>5.15  Risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> (TD)</h2>
<p class="First">A potentially irreversible syndrome of involuntary, dyskinetic movements may develop in patients treated with neuroleptic drugs.  In an animal model of <span class="product-label-link" type="condition" conceptid="376969" conceptname="Orofacial dyskinesia">orofacial dyskinesias</span>, acute administration of reserpine, a monoamine depletor, has been shown to produce vacuous chewing in rats.  Although the pathophysiology of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> remains incompletely understood, the most commonly accepted hypothesis of the mechanism is that prolonged post-synaptic dopamine receptor blockade leads to supersensitivity to dopamine.  Neither reserpine nor tetrabenazine tablets, which are dopamine depletors, have been reported to cause clear <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> in humans, but as pre-synaptic dopamine depletion could theoretically lead to supersensitivity to dopamine, and tetrabenazine tablets can cause the <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> also known to be associated with neuroleptics (e.g., <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>), physicians should be aware of the possible risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. If signs and symptoms of TD appear in a patient treated with tetrabenazine tablets, drug discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9965e8c0-d615-4fef-8291-c19cd0180a12"></a><a name="section-6.16"></a><p></p>
<h2>5.16 Use in Patients with Concomitant Illnesses</h2>
<p class="First">Clinical experience with tetrabenazine tablets in patients with systemic illnesses is limited.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</span></p>
<p>Tetrabenazine tablets may increase the risk for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality in patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or in patients with diseases, conditions, or treatments that cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality.  Tetrabenazine tablets are contraindicated in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or who are actively suicidal <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>, and <a href="#ID_7212ba12-d790-498e-81a3-f93f8379099d">Use in Specific Populations (8.7)</a>].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></span></p>
<p>Tetrabenazine tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.4)</a>, <a href="#S4">Contraindications (4)</a>, <a href="#S8.6">Use in Specific Populations (8.6)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
<p><span class="Bold">Heart Disease </span></p>
<p>Tetrabenazine tablets have not been evaluated in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease.  Patients with these diagnoses were excluded from premarketing clinical trials.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.17"></a><a name="section-6.17"></a><p></p>
<h2>5.17   Binding to Melanin-Containing Tissues</h2>
<p class="First">Since tetrabenazine tablets or its metabolites bind to melanin-containing tissues, it could accumulate in these tissues over time. This raises the possibility that tetrabenazine tablets may cause toxicity in these tissues after extended use. Neither ophthalmologic nor microscopic examination of the eye was conducted in the chronic toxicity study in dogs. Ophthalmologic monitoring in humans was inadequate to exclude the possibility of injury occurring after long-term exposure.</p>
<p>The clinical relevance of tetrabenazine binding to melanin-containing tissues is unknown. Although there are no specific recommendations for periodic ophthalmologic monitoring, prescribers should be aware of the possibility of long-term ophthalmologic effects <span class="Italics">[see <a href="#S12.2">Clinical Pharmacology (12.2)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-7"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following risks are discussed in greater detail in other sections of the labeling: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and suicidality <span class="Italics">[see <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</dd>
<dt>•</dt>
<dd>Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a667707c-29dd-4b60-9de1-58fdb27ec202"></a><a name="section-7.1"></a><p></p>
<h2>6.1 Commonly Observed Adverse Reactions in Controlled Clinical Trials</h2>
<p class="First">The most common adverse reactions from Table 1 occurring in over 10% of tetrabenazine-treated patients, and at least 5% greater than placebo, were sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (31%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (22%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (22%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (19%), <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (19%), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (13%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-7.2"></a><p></p>
<h2>6.1   Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>During its development, tetrabenazine tablets were administered to 773 unique subjects and patients. The conditions and duration of exposure to tetrabenazine tablets varied greatly, and included single and multiple dose clinical pharmacology studies in healthy volunteers (n=259) and open-label (n=529) and double-blind studies (n=84) in patients.</p>
<p>In a randomized, 12-week, placebo-controlled clinical trial of HD subjects, adverse reactions (ARs) were more common in the tetrabenazine tablets group than in the placebo group.  Forty-nine of 54 (91%) patients who received tetrabenazine tablets experienced one or more ARs at any time during the study. The ARs most commonly reported (over 10%, and at least 5% greater than placebo) were sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (31% vs. 3% on placebo), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (22% vs. 13% on placebo), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (22% vs. 0% on placebo), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (19% vs. 0% on placebo), <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (19% vs. 0% on placebo), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (13% vs. 7% on placebo).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27880145-4b6f-43cf-adaf-3aecc30a3210"></a><a name="section-7.2.1"></a><p></p>
<p class="First"><span class="Bold">Adverse Reactions Occurring in ≥4% Patients              </span></p>
<p>The number and percentage of the most commonly reported AEs that occurred at any time during the study in ≥4% of tetrabenazine-treated patients, and with a greater frequency than in placebo-treated patients, are presented in Table 1 in decreasing order of frequency within body systems for the tetrabenazine tablets group.</p>
<a name="_RefID0EQ4AE"></a><table width="85.1%">
<caption><span>Table 1.  Treatment Emergent Adverse Reactions in Patients Treated with Tetrabenazine Tablets and with a Greater Frequency than Placebo in the 12-Week, Double-Blind, Placebo-Controlled Trial of Tetrabenazine Tablets </span></caption>
<col width="28%">
<col width="30%">
<col width="24%">
<col width="16%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Body System</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">AE Term</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Tetrabenazine Tablets</span><br><span class="Bold">n = 54</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">n = 30</span><br><span class="Bold">n (%)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule" rowspan="7" valign="middle"><p class="First">PSYCHIATRIC DISODERS</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Sedation/<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">17 (31%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">1 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12 (22%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (19%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>/<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety aggravated</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8 (15%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite decreased</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive reaction</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" rowspan="7"><p class="First">CENTRAL &amp; PERIPHERAL NERVOUS SYSTEM</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">10 (19%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">Balance difficulty</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>/<span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">5 (9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait unsteady</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" rowspan="2"><p class="First">GASTROINTESTINAL SYSTEM DISORDERS</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">7 (13%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (3%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" rowspan="4"><p class="First">BODY AS A WHOLE - GENERAL</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">12 (22%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (13%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8 (15%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (13%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="443419" conceptname="Laceration - injury">Laceration</span> (head)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">3 (6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" rowspan="3"><p class="First"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">RESPIRATORY SYSTEM DISORDERS</span></p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">6 (11%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (7%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">URINARY SYSTEM DISORDERS</p></td>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-</p></td>
</tr>
</tbody>
</table>
<p>Dose escalation was discontinued or dosage of study drug was reduced because of one or more ARs in 28 of 54 (52%) patients randomized to tetrabenazine tablets.  These ARs consisted of sedation (15), <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (7), <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> (4), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (3), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (2), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (1) and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1). Some patients had more than one AR and are, therefore, counted more than once.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_995db7a1-8ed0-4f24-809b-e44f2ba81a3d"></a><a name="section-7.2.2"></a><p></p>
<p class="First"><span class="Bold">Adverse Reactions Due to <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> (EPS)</span></p>
<p>The following table describes the incidence of events considered to be extrapyramidal adverse reactions.</p>
<a name="_RefID0ENJAG"></a><table width="65%">
<caption><span>Table 2. Treatment Emergent EPS in Patients Treated with Tetrabenazine Tablets Occurring with a Greater Frequency than Placebo in the 12-Week, Double-Blind, Placebo-Controlled Trial of Tetrabenazine Tablets </span></caption>
<col width="26%">
<col width="26%">
<col width="23%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top"><span class="Bold">Event</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Patient (%) reporting event</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Tetrabenazine Tablets</span><br><span class="Bold">n = 54</span><br>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">n = 30</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Patients with the following adverse event preferred terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Patients with the following adverse event preferred terms were counted in this category: <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>. </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">10 (19%)</p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Extrapyramidal event<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center"><p class="First">8 (15%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Any extrapyramidal event</p></td>
<td class="Botrule Rrule" align="center"><p class="First">18 (33%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>Patients may have had events in more than one category.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-7.3"></a><p></p>
<h2>6.3  Laboratory Tests</h2>
<p class="First">No clinically significant changes in laboratory parameters were reported in clinical trials with tetrabenazine tablets.  In controlled clinical trials, tetrabenazine tablets caused a small mean increase in <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), laboratory values as compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f10dbc42-9259-42a9-ad4b-38eea38d35d4"></a><a name="section-7.4"></a><p></p>
<h2>6.4 Vital Signs</h2>
<p class="First">In controlled clinical trials, tetrabenazine tablets did not affect blood pressure, pulse, and body weight.  Orthostatic blood pressure was not consistently measured in the tetrabenazine tablets clinical trials.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-8"></a><p></p>
<h1>7   DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-8.1"></a><p></p>
<h2>7.1   Strong CYP2D6 Inhibitors</h2>
<p class="First"><span class="Italics">In vitro</span> studies indicate that α-HTBZ and β-HTBZ are substrates for CYP2D6.  Strong CYPD6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) markedly increase exposure to these metabolites. A reduction in tetrabenazine tablets dose may be necessary when adding a strong CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, quinidine) in patients maintained on a stable dose of tetrabenazine tablets.  The daily dose of tetrabenazine tablets should not exceed 50 mg per day and the maximum single dose of tetrabenazine tablets should not exceed 25 mg in patients taking strong CYP2D6 inhibitors <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>, <a href="#S5.3">Warnings and Precautions (5.2)</a>,<a href="#S8.8">Use in Specific Populations (8.8)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-8.2"></a><p></p>
<h2>7.2   Reserpine</h2>
<p class="First">Reserpine binds irreversibly to VMAT2 and the duration of its effect is several days.  Prescribers should wait for <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> to reemerge before administering tetrabenazine tablets to avoid overdosage and major depletion of serotonin and norepinephrine in the CNS. At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets. Tetrabenazine tablets and reserpine should not be used concomitantly <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.15">Warnings and Precautions (5.12)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-8.3"></a><p></p>
<h2>7.3   Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">Tetrabenazine tablets are contraindicated in patients taking MAOIs. Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#S5.15">Warnings and Precautions (5.12)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-8.4"></a><p></p>
<h2>7.4   Alcohol</h2>
<p class="First">Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> <span class="Italics">[see <a href="#ID_8b52983b-2e7c-4fe7-9438-0d3c29b1d8e8">Warnings and Precautions (5.10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-8.5"></a><p></p>
<h2>7.5   Drugs that Cause QTc Prolongation</h2>
<p class="First">Since tetrabenazine tablets cause a small increase in QTc prolongation (about 8 msec), the concomitant use with other drugs that are known to cause QTc prolongation should be avoided including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide), and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval.  Tetrabenazine tablets should also be avoided in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span> and in patients with a history of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.  Certain circumstances may increase the risk of the occurrence of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> and/or <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> in association with the use of drugs that prolong the QTc interval, including (1) <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; (2) <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval <span class="Italics">[see Warnings and Precautions (<a href="#S5.11">5.11</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">5.12</a>), <a href="#S7.6">Drug Interactions (7.6)</a>, and <a href="#S12.2">Clinical Pharmacology (12.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-8.6"></a><p></p>
<h2>7.6   Neuroleptic Drugs</h2>
<p class="First">Adverse reactions associated with tetrabenazine tablets, such as QTc prolongation, NMS, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorders</span>, may be exaggerated by concomitant use of dopamine antagonists, including antipsychotics (e.g., chloropromazine, haloperidol, olanzapine, risperidone, thioridazine, ziprasidone) <span class="Italics">[see Warnings and Precautions (<a href="#S5.5">5.5</a>, <a href="#S5.9">5.9</a>, <a href="#S5.11">5.11</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">5.12</a>) and <a href="#S7.5">Drug Interactions (7.5)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-9"></a><p></p>
<h1>8    USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-9.1"></a><p></p>
<h2>8.1   Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_bcd0e206-46d2-45e2-ad5c-973d69f811fe"></a><a name="section-9.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category C</span></span></p>
<p>There are no adequate and well-controlled studies in pregnant women. Tetrabenazine tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>Tetrabenazine had no clear effects on embryo-fetal development when administered to pregnant rats throughout the period of organogenesis at oral doses up to 30 mg/kg/day (or 3 times the maximum recommended human dose [MRHD] of 100 mg/day on a mg/m<span class="Sup">2</span> basis). Tetrabenazine had no effects on embryo-fetal development when administered to pregnant rabbits during the period of organogenesis at oral doses up to 60 mg/kg/day (or 12 times the MRHD on a mg/m<span class="Sup">2</span> basis).  Because neither rat nor rabbit dosed with tetrabenazine produce 9-desmethyl-beta-DHTBZ, a major human metabolite, these studies may not have adequately addressed the potential effects of tetrabenazine on embryo-fetal development in humans.</p>
<p>When tetrabenazine was administered to female rats (doses of 5, 15, and 30 mg/kg/day) from the beginning of organogenesis through the lactation period, an increase in <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and offspring postnatal mortality was observed at 15 and 30 mg/kg/day and delayed pup maturation was observed at all doses. The no-effect dose for <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> and postnatal mortality was 0.5 times the MRHD on a mg/m<span class="Sup">2</span> basis.  Because rats dosed with tetrabenazine do not produce 9-desmethyl-beta-DHTBZ, a major human metabolite, this study may not have adequately assessed the potential effects of tetrabenazine on the offspring of women exposed <span class="Italics">in utero</span> and via lactation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-9.2"></a><p></p>
<h2>8.2   Labor and Delivery</h2>
<p class="First">The effect of tetrabenazine tablets on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-9.3"></a><p></p>
<h2>8.3   Nursing Mothers</h2>
<p class="First">It is not known whether tetrabenazine tablets or its metabolites are excreted in human milk. </p>
<p>Since many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from tetrabenazine tablets, a decision should be made whether to discontinue nursing or to discontinue tetrabenazine tablets, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-9.4"></a><p></p>
<h2>8.4   Pediatric Use</h2>
<p class="First">The safety and efficacy of tetrabenazine tablets in children have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-9.5"></a><p></p>
<h2>8.5   Geriatric Use</h2>
<p class="First">The pharmacokinetics of tetrabenazine tablets and its primary metabolites have not been formally studied in geriatric subjects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-9.6"></a><p></p>
<h2>8.6   Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First">The use of tetrabenazine tablets in patients with liver disease is contraindicated <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.4)</a>, <a href="#S4">Contraindications (4)</a>, <a href="#ID_9965e8c0-d615-4fef-8291-c19cd0180a12">Warnings and Precautions (5.16)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7212ba12-d790-498e-81a3-f93f8379099d"></a><a name="section-9.7"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and Suicidality</h2>
<p class="First">Patients with HD are at increased risk for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality), and tetrabenazine tablets increases these risks. Tetrabenazine tablets are contraindicated in patients with untreated or inadequately treated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or who are actively suicidal.  Tetrabenazine tablets may increase the risk for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality in patients with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or in patients with diseases, conditions, or treatments that cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span></p>
<p>Symptoms of sadness, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, withdrawal, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> (<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>), <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> may increase with tetrabenazine tablets.  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>/worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> was noted in 35% of tetrabenazine-treated patients during studies with tetrabenazine tablets.</p>
<p><span class="Bold">Suicidality</span></p>
<p>The rate of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicide</span> among individuals with Huntington’s disease ranges from 3-13% and over 25% of patients with HD attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> at some point in their illness.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-9.8"></a><p></p>
<h2>8.8 Use in Poor or Extensive CYP2D6 Metabolizers</h2>
<p class="First">Patients who require doses of tetrabenazine tablets greater than 50 mg per day, should be first tested and genotyped to determine if they are poor (PMs) or extensive metabolizers (EMs) by their ability to express the drug metabolizing enzyme, CYP2D6.  The dose of tetrabenazine tablets should then be individualized accordingly to their status as either poor (PMs) or extensive metabolizers (EMs) <span class="Italics">[see <a href="#_Ref">Dosage and Administration (2.2)</a>, Warnings and Precautions (<a href="#S5.3">5.2</a>, <a href="#S5.4">5.4</a>), and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].  </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20875d90-ba7b-4cd8-b8ba-74423404882c"></a><a name="section-9.8.1"></a><p></p>
<p class="First"><span class="Bold">Poor Metabolizers</span></p>
<p>Poor CYP2D6 metabolizers (PMs) will have substantially higher levels of exposure to the primary metabolites (about 3-fold for α-HTBZ and 9-fold for β-HTBZ) compared to EMs. The dosage should, therefore, be adjusted according to a patient's CYP2D6 metabolizer status by limiting a single dose to a maximum of 25 mg and the recommended daily dose to not exceed a maximum of 50 mg/day in patients who are CYP2D6 PMs <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, Warnings and Precautions (<a href="#S5.3">5.2</a>, <a href="#S5.4">5.4</a>), and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b009455-0217-4a76-bfe9-5fd013497577"></a><a name="section-9.8.2"></a><p></p>
<p class="First"><span class="Bold">Extensive/Intermediate Metabolizers    </span></p>
<p>In extensive (EMs) or intermediate metabolizers (IMs), the dosage of tetrabenazine tablets can be titrated to a maximum single dose of 37.5 mg and a recommended maximum daily dose of 100 mg <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>, and <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc"></a><a name="section-9.9"></a><p></p>
<h2>8.9 Use in Patients at Risk from QTc Prolongation</h2>
<p class="First">Tetrabenazine tablets cause a small increase in QTc interval (8 msec).  It should be avoided in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, or a history of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (e.g., <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>), or in combination with other drugs that are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide), and Class III (e.g., amiodarone, sotalol), antiarrhythmic medications or any other medications known to prolong the QTc interval <span class="Italics">[see Warnings and Precautions (<a href="#S5.5">5.5</a>, <a href="#S5.11">5.11</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">5.12</a>), Drug Interactions (<a href="#S7.5">7.5</a>, <a href="#S7.6">7.6</a>), and <a href="#S12.2">Clinical Pharmacology (12.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_94796d35-ba18-45b5-9473-2efecfadf19c"></a><a name="section-9.10"></a><p></p>
<h2>8.10 Use in Patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">The effects of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> in the pharmacokinetics of tetrabenazine tablets and its primary metabolites have not been formally studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-10"></a><p></p>
<h1>9   DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-10.1"></a><p></p>
<h2>9.1   Controlled Substance Class</h2>
<p class="First">Tetrabenazine tablets are not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-10.2"></a><p></p>
<h2>9.2   Abuse</h2>
<p class="First">Clinical trials did not reveal any tendency for <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug seeking behavior</span>, though these observations were not systematic.  Abuse has not been reported from the postmarketing experience in countries where tetrabenazine tablets have been marketed.</p>
<p>As with any CNS-active drug, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of tetrabenazine tablets misuse or abuse (such as development of tolerance, increasing dose requirements, drug-seeking behavior). </p>
<p>Abrupt discontinuation of tetrabenazine tablets from patients did not produce symptoms of withdrawal or a discontinuation syndrome; only symptoms of the original disease were observed to re-emerge <span class="Italics">[see <a href="#ID_f2b8c66d-d835-447c-880e-c9c519c042c2">Dosage and Administration (2.5)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-11"></a><p></p>
<h1>10   OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d010630-811a-4250-b37b-25647a3d4736"></a><a name="section-11.1"></a><p></p>
<h2>10.1 Human Experience</h2>
<p class="First">Three episodes of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurred in the open-label trials performed in support of registration.  Eight cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with tetrabenazine tablets have been reported in the literature. The dose of tetrabenazine tablets in these patients ranged from 100 mg to 1g. Adverse reactions associated with tetrabenazine tablets <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, sedation, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, rubor, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_20df10b2-f1e3-458b-92ff-d57ac8c70ca3"></a><a name="section-11.2"></a><p></p>
<h2>10.2 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span></h2>
<p class="First">Treatment should consist of those general measures employed in the management of overdosage with any CNS-active drug. General supportive and symptomatic measures are recommended. Cardiac rhythm and vital signs should be monitored. In managing overdosage, the possibility of multiple drug involvement should always be considered. The physician should consider contacting a poison control center on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the Physicians’ Desk Reference<span class="Sup">®</span>(PDR<span class="Sup">®</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-12"></a><p></p>
<h1>11   DESCRIPTION</h1>
<p class="First">Tetrabenazine tablets are a monoamine depletor for oral administration. The molecular weight of tetrabenazine is 317.43; the pKa is 6.51. Tetrabenazine is a hexahydro-dimethoxy-benzoquinolizine derivative and has the following chemical name: cis rac –1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-one.</p>
<p>The empirical formula C<span class="Sub">19</span>H<span class="Sub">27</span>NO<span class="Sub">3 </span>is represented by the following structural formula:</p>
<div class="Figure">
<a name="id1556"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&amp;name=image-01.jpg">
</div>
<p>Tetrabenazine is a white to slightly yellow crystalline powder that is sparingly soluble in water and soluble in ethanol.</p>
<p>Each tetrabenazine tablet contains either 12.5 or 25 mg of tetrabenazine as the active ingredient. </p>
<p>Tetrabenazine tablets contain tetrabenazine as the active ingredient and the following inactive ingredients: lactose, magnesium stearate, maize starch, and talc.  The 25 mg strength tablet also contains yellow iron oxide as an inactive ingredient. </p>
<p>Tetrabenazine tablets are supplied as a yellowish-buff scored tablet containing 25 mg of tetrabenazine tablets or as a white non-scored tablet containing 12.5 mg of tetrabenazine tablets.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-13"></a><p></p>
<h1>12   CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-13.1"></a><p></p>
<h2>12.1   Mechanism of Action</h2>
<p class="First">The precise mechanism by which tetrabenazine tablets exerts its anti-<span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> effects is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals.  Tetrabenazine reversibly inhibits the human vesicular monoamine transporter type 2 (VMAT2) (K<span class="Sub">i</span> ≈ 100 nM), resulting in decreased uptake of monoamines into synaptic <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> and depletion of monoamine stores.  Human VMAT2 is also inhibited by dihydrotetrabenazine (HTBZ), a mixture of α-HTBZ and β-HTBZ. α- and β-HTBZ, major circulating metabolites in humans, exhibit high <span class="Italics">in vitro</span> binding affinity to bovine VMAT2.  Tetrabenazine exhibits weak <span class="Italics">in vitro</span> binding affinity at the dopamine D2 receptor (K<span class="Sub">i</span> = 2100 nM).</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-13.2"></a><p></p>
<h2>12.2   Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9894bb39-28f8-49e4-a0a3-43be3894ad52"></a><a name="section-13.2.1"></a><p></p>
<p class="First"><span class="Bold">QTc Prolongation</span></p>
<p>The effect of a single 25 or 50 mg dose of tetrabenazine tablets on the QT interval was studied in a randomized, double-blind, placebo controlled crossover study in healthy male and female subjects with moxifloxacin as a positive control.  At 50 mg, tetrabenazine tablets caused an approximately 8 msec mean increase in QTc (90% CI: 5.0, 10.4 msec).  Additional data suggest that inhibition of CYP2D6 in healthy subjects given a single 50 mg dose of tetrabenazine tablets does not further increase the effect on the QTc interval.  Effects at higher exposures to either tetrabenazine tablets or its metabolites have not been evaluated <span class="Italics">[see Warnings and Precautions (<a href="#S5.11">5.11</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">5.12</a>), Drug Interactions (<a href="#S7.5">7.5</a>, <a href="#S7.6">7.6</a>), and <a href="#ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc">Use in Specific Populations (8.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a7230c25-471f-4b3f-b745-08e3b77b4436"></a><a name="section-13.2.2"></a><p></p>
<p class="First"><span class="Bold">Melanin Binding</span></p>
<p>Tetrabenazine or its metabolites bind to melanin-containing tissues (i.e., eye, skin, fur) in pigmented rats.  After a single oral dose of radiolabeled tetrabenazine, radioactivity was still detected in eye and fur at 21 days post dosing <span class="Italics">[see <a href="#S5.17">Warnings and Precautions (5.17)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-13.3"></a><p></p>
<h2>12.3  Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bc0fe4e6-4514-415d-9320-e8e2e74d13bd"></a><a name="section-13.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Following oral administration of tetrabenazine, the extent of absorption is at least 75%.  After single oral doses ranging from 12.5 to 50 mg, plasma concentrations of tetrabenazine are generally below the limit of detection because of the rapid and extensive hepatic metabolism of tetrabenazine by carbonyl reductase to the active metabolites α-HTBZ and β-HTBZ.  α-HTBZ and β-HTBZ  are metabolized principally by CYP2D6.  Peak plasma concentrations (C<span class="Sub">max</span>) of α-HTBZ and β-HTBZ are reached within 1 to 1½ hours post-dosing.  α-HTBZ is subsequently metabolized to a minor metabolite, 9-desmethyl-α-DHTBZ. β-HTBZ is subsequently, metabolized to another major circulating metabolite, 9-desmethyl-β-DHTBZ, for which C<span class="Sub">max</span> is reached approximately 2 hours post-dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4846ba20-4a69-4fb7-8801-6b0e96c02f1f"></a><a name="section-13.3.2"></a><p></p>
<p class="First"><span class="Bold">Food Effects</span></p>
<p>The effects of food on the bioavailability of tetrabenazine tablets were studied in subjects administered a single dose with and without food.  Food had no effect on mean plasma concentrations, C<span class="Sub">max</span>, or the area under the concentration time course (AUC) of α-HTBZ or β-HTBZ. Tetrabenazine tablets can, therefore, be administered without regard to meals.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_17cd66a4-827b-4f0c-82bc-59ec7c3c07ca"></a><a name="section-13.3.3"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Results of PET-scan studies in humans show that radioactivity is rapidly distributed to the brain following intravenous injection of <span class="Sup">11</span>C-labeled tetrabenazine or α-HTBZ, with the highest binding in the striatum and lowest binding in the cortex. </p>
<p>The <span class="Italics">in vitro</span> protein binding of tetrabenazine, α-HTBZ, and β-HTBZ was examined in human plasma for concentrations ranging from 50 to 200 ng/mL.  Tetrabenazine binding ranged from 82% to 85%, α-HTBZ binding ranged from 60% to 68%, and β-HTBZ binding ranged from 59% to 63%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_635c8cab-d522-4ec4-b5a9-bbe8fba4218b"></a><a name="section-13.3.4"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>After oral administration in humans, at least 19 metabolites of tetrabenazine have been identified. α-HTBZ, β-HTBZ and 9-desmethyl-β-DHTBZ, are the major circulating metabolites, and they are, subsequently, metabolized to sulfate or glucuronide conjugates.  α-HTBZ and β-HTBZ are formed by carbonyl reductase that occurs mainly in the liver. α-HTBZ is O-dealkylated by CYP450 enzymes, principally CYP2D6, with some contribution of CYP1A2 to form 9-desmethyl-α-DHTBZ, a minor metabolite. β-HTBZ is O-dealkylated principally by CYP2D6 to form 9-desmethyl-β-DHTBZ.</p>
<p>The results of <span class="Italics">in vitro</span> studies do not suggest that tetrabenazine, α-HTBZ, or β-HTBZ are likely to result in clinically significant inhibition of CYP2D6, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A.   <span class="Italics">In vitro</span> studies suggest that neither tetrabenazine nor its α- or β-HTBZ metabolites are likely to result in clinically significant induction of CYP1A2, CYP3A4, CYP2B6, CYP2C8, CYP2C9, or CYP2C19.</p>
<p>Neither tetrabenazine nor its α- or β-HTBZ metabolites is likely to be a substrate or inhibitor of P-glycoprotein at clinically relevant concentrations <span class="Italics">in vivo</span>. </p>
<p>No <span class="Italics">in vitro</span> metabolism studies have been conducted to evaluate the potential of the 9-desmethyl-β-DHTBZ metabolite to interact with other drugs. The activity of this metabolite relative to the parent drug is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_772db41c-3f4f-42a1-b2a2-c4c02c7d8ffd"></a><a name="section-13.3.5"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>After oral administration, tetrabenazine is extensively hepatically metabolized, and the metabolites are primarily renally eliminated. α-HTBZ, β-HTBZ and 9-desmethyl-β-DHTBZ have half-lives of 7 hours, 5 hours and 12 hours respectively. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study in 6 healthy volunteers, approximately 75% of the dose was excreted in the urine and fecal recovery accounted for approximately 7-16% of the dose.  Unchanged tetrabenazine has not been found in human urine.  Urinary excretion of α-HTBZ or β-HTBZ accounted for less than 10% of the administered dose.  Circulating metabolites, including sulfate and glucuronide conjugates of HTBZ metabolites as well as products of oxidative metabolism, account for the majority of metabolites in the urine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8f89de20-15ae-4aee-9112-e74d7a1d4d5a"></a><a name="section-13.3.6"></a><p></p>
<p class="First"><span class="Bold">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_47567f87-de49-4dcf-a58f-96720050d80c"></a><a name="section-13.3.6.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Pediatric Patient</span></span></p>
<p>The pharmacokinetics of tetrabenazine tablets and its primary metabolites have not been studied in pediatric subjects <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Geriatric Patient</span></span></p>
<p>The pharmacokinetics of tetrabenazine tablets and its primary metabolites have not been formally studied in geriatric subjects <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Gender</span></span></p>
<p>There is no apparent effect of gender on the pharmacokinetics of α-HTBZ or β-HTBZ. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b7464abe-eaf3-4ef8-a6e1-3d53526ae8ff"></a><a name="section-13.3.6.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Race</span></span></p>
<p>Racial differences in the pharmacokinetics of tetrabenazine tablets and its primary metabolites have not been formally studied. </p>
<p><span class="Bold"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> on the pharmacokinetics of tetrabenazine tablets and its primary metabolites has not been studied.</p>
<p><span class="Bold"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>  </span></span></p>
<p>The disposition of tetrabenazine was compared in 12 patients with mild to moderate chronic liver impairment (Child-Pugh scores of 5-9) and 12 age- and gender-matched subjects with normal hepatic function who received a single 25 mg dose of tetrabenazine.  In patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, tetrabenazine plasma concentrations were similar to or higher than concentrations of α-HTBZ, reflecting the markedly decreased metabolism of tetrabenazine to α-HTBZ. The mean tetrabenazine C<span class="Sub">max</span> in hepatically impaired subjects was approximately 7- to 190-fold higher than the detectable peak concentrations in healthy subjects.  The elimination half-life of tetrabenazine in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was approximately 17.5 hours.  The time to peak concentrations (t<span class="Sub">max</span>) of α-HTBZ and β-HTBZ was slightly delayed in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to age-matched controls (1.75 hrs vs. 1.0 hrs), and the elimination half lives of the α-HTBZ and β-HTBZ were prolonged to approximately 10 and 8 hours, respectively.  The exposure to α-HTBZ and β-HTBZ was approximately 30-39% greater in patients with liver impairment than in age-matched controls.  The safety and efficacy of this increased exposure to tetrabenazine and other circulating metabolites are unknown so that it is not possible to adjust the dosage of tetrabenazine in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> to ensure safe use. Therefore, tetrabenazine is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S2.5">Dosage and Administration (2.4)</a>, <a href="#S4">Contraindications (4)</a>, <a href="#ID_9965e8c0-d615-4fef-8291-c19cd0180a12">Warnings and Precautions (5.16)</a>, and <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a240f004-d869-4dde-8210-4d008c25d399"></a><a name="section-13.3.6.3"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Patients Who Are Poor or Extensive CYP2D6 Metabolizers </span></span></p>
<p>Patients should be genotyped for drug metabolizing enzyme, CYP2D6, prior to treatment with daily doses of tetrabenazine tablets over 50 mg <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S5.4">Warnings and Precautions (5.4)</a>, and <a href="#S8.8">Use in Specific Populations (8.8)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Poor Metabolizers  </span></span></p>
<p>Although the pharmacokinetics of tetrabenazine tablets and its metabolites in subjects who do not express the drug metabolizing enzyme, CYP2D6, poor metabolizers, (PMs), have not been systematically evaluated, it is likely that the exposure to α-HTBZ and β-HTBZ would be increased similar to that observed in patients taking strong CYP2D6 inhibitors (3- and 9-fold, respectively).  Patients who are PMs should not be given doses greater than 50 mg per day and the maximum recommended single dose is 25 mg <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, Warnings and Precautions (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>, <a href="#S5.4">5.4</a>), and <a href="#S8.8">Use in Specific Populations (8.8)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Extensive or Intermediate CYP2D6 Metabolizers</span></span></p>
<p>In patients who express the enzyme, CYP2D6, (extensive [EMs] or intermediate [IMs] metabolizers), the maximum recommended daily dose is 100 mg per day, with a maximum recommended single dose of 37.5 mg <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S5.4">Warnings and Precautions (5.4)</a>, and <a href="#S8.8">Use in Specific Populations (8.8)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_62a4231e-cb52-4c87-aa6c-c4b8ef4b0ee3"></a><a name="section-13.3.6.4"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1b60ffd2-f51e-41a8-a198-b5e024107cda"></a><a name="section-13.3.7"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d69348d-0210-4f2d-9ef5-b093879df9a8"></a><a name="section-13.3.7.1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">CYP2D6 Inhibitors</span></span></p>
<p><span class="Italics">In vitro</span> studies indicate that α-HTBZ and β-HTBZ are substrates for CYP2D6.  The effect of CYP2D6 inhibition on the pharmacokinetics of tetrabenazine and its metabolites was studied in 25 healthy subjects following a single 50 mg dose of tetrabenazine given after 10 days of administration of the strong CYP2D6 inhibitor paroxetine 20 mg daily.  There was an approximately 30% increase in C<span class="Sub">max</span> and an approximately 3-fold increase in AUC for α-HTBZ in subjects given paroxetine prior to tetrabenazine compared to tetrabenazine given alone.  For β-HTBZ, the C<span class="Sub">max</span> and AUC were increased 2.4- and 9-fold, respectively, in subjects given paroxetine prior to tetrabenazine given alone. The elimination half-life of α-HTBZ and β-HTBZ was approximately 14 hours when tetrabenazine was given with paroxetine.</p>
<p>Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine) markedly increase exposure to these metabolites. The effect of moderate or weak CYP2D6 inhibitors such as duloxetine, terbinafine, amiodarone, or sertraline on the exposure to tetrabenazine tablets and its metabolites has not been evaluated <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.3)</a>, <a href="#S7.1">Drug Interactions (7.1)</a>, and <a href="#ID_396d16c9-e350-4b5d-80a5-b4d33973c8dc">Use in Specific Populations (8.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_37afac94-5188-4b11-a3a8-e107e2ecdbe5"></a><a name="section-13.3.7.2"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Digoxin</span></span></p>
<p>Digoxin is a substrate for P-glycoprotein.  A study in healthy volunteers showed that tetrabenazine tablets (25 mg twice daily for 3 days) did not affect the bioavailability of digoxin, suggesting that at this dose, tetrabenazine tablets does not affect P-glycoprotein in the intestinal tract.  <span class="Italics">In vitro</span> studies also do not suggest that tetrabenazine tablets or its metabolites are P-glycoprotein inhibitors.</p>
<p><span class="Bold"><span class="Italics">Reserpine</span></span></p>
<p>Tetrabenazine tablets are contraindicated in patients taking reserpine.  At least 20 days should elapse after stopping reserpine before starting tetrabenazine tablets <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">Warnings and Precautions (5.12)</a>, and <a href="#S7.2">Drug Interactions (7.2)</a>].</span></p>
<p><span class="Bold"><span class="Italics">Monoamine Oxidase Inhibitors (MAOIs)</span></span></p>
<p>Tetrabenazine tablets are contraindicated in patients taking MAOIs.  Tetrabenazine tablets should not be used in combination with an MAOI, or within a minimum or 14 days of discontinuing therapy with an MAOI <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_f744c52e-0e09-468a-aff5-096ccf1ffbb5">Warnings and Precautions (5.12)</a>, and <a href="#S7.3">Drug Interactions (7.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_51bf23fd-e5e8-4ca4-af32-092ddbd79393"></a><a name="section-13.3.7.3"></a><p></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-14"></a><p></p>
<h1>13   NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-14.1"></a><p></p>
<h2>13.1   Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_82e7f91d-ecbd-4ed7-8981-82b273b995f6"></a><a name="section-14.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>No increase in tumors was observed in p53<span class="Sup">+/-</span> transgenic mice treated orally with tetrabenazine at doses of 0, 5, 15 and 30 mg/kg/day for 26 weeks.  When compared to humans receiving a 50 mg dose of tetrabenazine tablets, mice dosed with a 30 mg/kg dose of tetrabenazine produce about one sixth the levels of 9-desmethyl-beta-DHTBZ, a major human metabolite.  Therefore, this study may not have adequately characterized the potential of tetrabenazine to be carcinogenic in people.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_63f65670-8120-4aaf-9ced-72600e40fe1e"></a><a name="section-14.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Tetrabenazine and metabolites α-HTBZ and β-HTBZ were negative in the <span class="Italics">in vitro</span> bacterial reverse mutation assay. Tetrabenazine was clastogenic in the <span class="Italics">in vitro</span> chromosome aberration assay in Chinese hamster ovary cells in the presence of metabolic activation. α-HTBZ and β-HTBZ were clastogenic in the <span class="Italics">in vitro</span> chromosome aberration assay in Chinese hamster lung cells in the presence and absence of metabolic activation.  <span class="Italics">In vivo</span> micronucleus tests were conducted in male and female rats and male mice. Tetrabenazine was negative in male mice and rats but produced an equivocal response in female rats. </p>
<p>Because the bioactivation system used in the <span class="Italics">in vitro</span> studies was hepatic S9 fraction prepared from rat, a species that, when dosed with tetrabenazine, does not produce 9-desmethyl-beta-DHTBZ, a major human metabolite, these studies may not have adequately assessed the potential of tetrabenazine tablets to be mutagenic in humans.  Furthermore, since the mouse produces very low levels of this metabolite when dosed with tetrabenazine, the <span class="Italics">in vivo</span> study may not have adequately assessed the potential of tetrabenazine tablets to be mutagenic in humans.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_72dea5bc-702a-4ccf-83cd-f9ebe3d01fd9"></a><a name="section-14.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>Oral administration of tetrabenazine (doses of 5, 15, or 30 mg/kg/day) to female rats prior to and throughout mating, and continuing through day 7 of gestation resulted in disrupted estrous cyclicity at doses greater than 5 mg/kg/day (less than the MRHD on a mg/m<span class="Sup">2 </span>basis).</p>
<p>No effects on mating and fertility indices or sperm parameters (motility, count, density) were observed when males were treated orally with tetrabenazine (doses of 5, 15 or 30 mg/kg/day; up to 3 times the MRHD on a mg/m<span class="Sup">2 </span>basis) prior to and throughout mating with untreated females.</p>
<p>Because rats dosed with tetrabenazine do not produce 9-desmethyl-beta-DHTBZ, a major human metabolite, these studies may not have adequately assessed the potential of tetrabenazine tablets to impair fertility in humans.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-15"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8e7d568d-0290-4e6e-b9f9-93d8595ec3fa"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Study 1</span></p>
<p>The efficacy of tetrabenazine tablets as a treatment for the <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> of Huntington's disease was established primarily in a randomized, double-blind, placebo-controlled multi-center trial (Study 1) conducted in ambulatory patients with a diagnosis of HD. The diagnosis of HD was based on family history, neurological exam, and genetic testing. Treatment duration was 12 weeks, including a 7-week dose titration period and a 5-week maintenance period followed by a 1-week washout.  The dose of tetrabenazine tablts was started at 12.5 mg per day and titrated upward at weekly intervals in 12.5 mg increments until satisfactory control of <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> was achieved, until intolerable side effects occurred, or until a maximal dose of 100 mg per day was reached.</p>
<p>The primary efficacy endpoint was the Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Score, an item of the Unified Huntington's Disease Rating Scale (UHDRS).  On this scale, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> is rated from 0 to 4 (with 0 representing no <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>) for 7 different parts of the body. The total score ranges from 0 to 28.</p>
<p>As shown in Figure 1, Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Scores for subjects in the drug group declined by an estimated 5.0 units during maintenance therapy (average of Week 9 and Week 12 scores versus baseline), compared to an estimated 1.5 units in the placebo group. The treatment effect of 3.5 units was statistically significant.  At the Week 13 follow-up in Study 1 (1 week after discontinuation of the study medication), the Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Scores of subjects receiving tetrabenazine tablets returned to baseline.</p>
<div class="Figure">
<a name="id1970"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&amp;name=xenazine-02.jpg">
</div>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">(error bars are ± s.e.m.)            </span><br><span class="Bold">*p&lt;0.05          </span></p></td></tr></tbody>
</table>
<p><span class="Bold">Figure 1.  Mean ± s.e.m. Changes from Baseline in Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Score in 84 HD Subjects Treated with Tetrabenazine Tablets (n=54) or Placebo (n=30)</span></p>
<p>Figure 2 illustrates the cumulative percentages of patients from the tetrabenazine tablets and placebo treatment groups who achieved the level of reduction in the Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Score shown on the X axis.  The left-ward shift of the curve (toward greater improvement) for tetrabenazine-treated patients indicates that these patients were more likely to have any given degree of improvement in <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> score. Thus, for example, about 7% of placebo patients had a 6-point or greater improvement compared to 50% of tetrabenazine-treated patients. The percentage of patients achieving reductions of at least 10, 6, and 3-points from baseline to Week 12 are shown in the inset table. </p>
<div class="Figure">
<a name="id1982"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&amp;name=xenazine-03.jpg">
</div>
<p><span class="Bold">Figure 2. Cumulative Percentage of Patients with Specified Changes from Baseline in Total <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> Score. </span>The Percentages of Randomized Patients within each treatment group who completed Study 1 were: Placebo 97%, Tetrabenazine 91%.</p>
<p>A Physician-rated Clinical Global Impression (CGI) favored tetrabenazine tablets statistically.  In general, measures of functional capacity and cognition showed no difference between tetrabenazine tablets and placebo. However, one functional measure (Part 4 of the UHDRS), a 25-item scale assessing the capacity for patients to perform certain activities of daily living, showed a decrement for patients treated with tetrabenazine tablets compared to placebo, a difference that was nominally statistically significant.  A 3-item cognitive battery specifically developed to assess cognitive function in patients with HD (Part 2 of the UHDRS) also showed a decrement for patients treated with tetrabenazine tablets compared to placebo, but the difference was not statistically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ca04a8ab-3684-4c44-b273-af3851869af1"></a><a name="section-15.2"></a><p></p>
<p class="First"><span class="Bold">Study 2</span></p>
<p>A second controlled study was performed in patients who had been treated with open-label tetrabenazine tablets for at least 2 months (mean duration of treatment was 2 years). They were randomized to continuation of tetrabenazine tablets at the same dose (n=12) or to placebo (n=6) for three days, at which time their <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> scores were compared.  Although the comparison did not reach statistical significance (p=0.1), the estimate of the treatment effect was similar to that seen in Study 1 (about 3.5 units).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S16.1"></a><a name="section-16.1"></a><p></p>
<h2>16.1   How Supplied</h2>
<p class="First">Tetrabenazine tablets are available in the following strengths and packages:</p>
<p>The 12.5 mg tetrabenazine tablets are white, cylindrical biplanar tablets with beveled edges, non-scored, embossed on one side with "CL" and "12.5". Bottles of 112:   NDC 68682-421-12.</p>
<p>The 25 mg tetrabenazine tablets are yellowish-buff, cylindrical biplanar tablets with beveled edges, scored, embossed on one side with "CL" and "25". Bottles of 112:   NDC 68682-422-25.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="S16.2"></a><a name="section-16.2"></a><p></p>
<h2>16.2   Storage</h2>
<p class="First">Store at 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-17"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved Medication Guide</p>
<p>Physicians are advised to discuss the following issues with patients and their families: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c76a26ab-fecc-4798-ba91-178765e92c92"></a><a name="section-17.1"></a><p></p>
<h2>17.1 Risk of Suicidality</h2>
<p class="First">Patients and their families should be told that tetrabenazine tablets may increase the risk of suicidal thinking and behaviors.  Patients and their families should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and should report it immediately to the patient’s physician <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>, and <a href="#ID_7212ba12-d790-498e-81a3-f93f8379099d">Use in Specific Populations (8.7)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3831b742-e496-40e3-ab89-92b39d3c8522"></a><a name="section-17.2"></a><p></p>
<h2>17.2 Risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">Patients and their families should be told that tetrabenazine tablets may cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or may worsen pre-existing <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. They should be encouraged to be alert to the emergence of sadness, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, withdrawal, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span> (<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>), <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> and to report such symptoms promptly to the patient's physician <span class="Italics">[see <a href="#S4">Contraindications (4)</a>, <a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">Warnings and Precautions (5.3)</a>, and <a href="#ID_7212ba12-d790-498e-81a3-f93f8379099d">Use in Specific Populations (8.7)</a>]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1635dc3c-3b09-4c7b-8bcc-b380bc812604"></a><a name="section-17.3"></a><p></p>
<h2>17.3 Dosing of Tetrabenazine Tablets</h2>
<p class="First">Patients and their families should be told that the dose of tetrabenazine tablets will be titrated up slowly to the dose that is best for each patient. Sedation, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and difficulty swallowing may occur.  Such symptoms should be promptly reported to the physician and the tetrabenazine tablets dose may need to be reduced or discontinued <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, and Warnings and Precautions (<a href="#ID_7df858eb-c605-4255-ad82-76d29f258a50">5.3</a>, <a href="#S5.6">5.6</a>, <a href="#S5.7">5.7</a>, <a href="#S5.9">5.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_13a71b89-772d-4f47-bb74-bb6f8a9f703f"></a><a name="section-17.4"></a><p></p>
<h2>17.4 Risk of Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Patients should be told that tetrabenazine tablets may induce sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and may impair the ability to perform tasks that require complex motor and mental skills. Patients should be advised that until they learn how they respond to tetrabenazine tablets, they should be careful doing activities that require them to be alert, such as driving a car or operating machinery <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d69ebcde-5dce-41f2-a401-bd4998eda1bf"></a><a name="section-17.5"></a><p></p>
<h2>17.5 Interaction with Alcohol </h2>
<p class="First">Patients and their families should be advised that alcohol may potentiate the sedation induced by tetrabenazine tablets <span class="Italics">[see <a href="#ID_8b52983b-2e7c-4fe7-9438-0d3c29b1d8e8">Warnings and Precautions (5.10)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_287f874c-472a-40ea-8605-4e2616fdcf40"></a><a name="section-17.6"></a><p></p>
<h2>17.6 Usage in Pregnancy</h2>
<p class="First">Patients and their families should be advised to notify the physician if the patient becomes pregnant or intends to become pregnant during tetrabenazine tablets therapy, or is breast-feeding or intending to breast-feed an infant during therapy <span class="Italics">[see <a href="#S5.14">Warnings and Precautions (5.14)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55791a33-a7fe-4bc0-b710-2146555debc0"></a><a name="section-17.7"></a><p></p>
<h2>17.7 General Advice</h2>
<p class="First">Patients and their families should be advised to notify the physician of all medications the patient is taking and to consult with the physician before starting any new medications. <br></p>
<p>Manufactured for: </p>
<p>Oceanside Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807 USA</p>
<p>By: <br>Recipharm Fontaine SAS</p>
<p>Rue des Pres Potets, 21121 Fontaine-les-Dijon, France</p>
<p>Made in France</p>
<p>Rev. 02/2015</p>
<p>9443700</p>
<p>607470A</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Medguide"></a><a name="section-18"></a><p></p>
<h1>MEDICATION GUIDE<br>
</h1>
<p class="First"><span class="Bold">Tetrabenazine Tablets</span><br>Read the Medication Guide that comes with tetrabenazine tablets before you start taking it and each time you refill the prescription. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.  You should share this information with your family members and caregivers.</p>
<p><span class="Bold">What is the most important information I should know about tetrabenazine tablets?</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Tetrabenazine tablets can cause serious side effects, including:</span><dl>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">suicidal thoughts</span></dd>
<dt>•</dt>
<dd><span class="Bold">suicidal actions</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>You should not start taking tetrabenazine tablets if you are depressed (have untreated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that is not well controlled by medicine) <span class="Bold">or</span> have suicidal thoughts. </dd>
<dt>•</dt>
<dd>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is especially important when tetrabenazine tablets are started and when the dose is changed.</dd>
</dl>
<p><span class="Bold">Call the doctor right away if you become depressed or have any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you: </span></p>
<dl>
<dt>•</dt>
<dd>feel sad or have <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> spells</dd>
<dt>•</dt>
<dd>lose interest in seeing your friends or doing things you used to enjoy</dd>
<dt>•</dt>
<dd>sleep a lot <span class="Bold">more</span> or a lot <span class="Bold">less</span> than usual</dd>
<dt>•</dt>
<dd>feel unimportant</dd>
<dt>•</dt>
<dd>feel guilty</dd>
<dt>•</dt>
<dd>feel hopeless or helpless</dd>
<dt>•</dt>
<dd>more <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span>, angry or aggressive than usual</dd>
<dt>•</dt>
<dd>more or less hungry than usual or notice a big change in your body weight</dd>
<dt>•</dt>
<dd>have trouble paying attention</dd>
<dt>•</dt>
<dd>feel tired or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> all the time</dd>
<dt>•</dt>
<dd>have thoughts about hurting yourself or ending your life</dd>
</dl>
<p><span class="Bold">What is tetrabenazine tablets?</span></p>
<p>Tetrabenazine tablets are a medicine that is used to treat the involuntary movements (<span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>) of Huntington's disease.  Tetrabenazine tablets do not cure the cause of the involuntary movements, and it does not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. </p>
<p>It is not known whether tetrabenazine tablets are safe and effective in children.</p>
<p><span class="Bold">Who should not take tetrabenazine tablets?</span></p>
<p><span class="Bold">Do not take tetrabenazine tablets if you:</span></p>
<dl>
<dt>•</dt>
<dd>are depressed or have thoughts of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. See "What is the most important information I should know about tetrabenazine<span class="Underline"> tablets</span>?"</dd>
<dt>•</dt>
<dd>have liver problems.</dd>
<dt>•</dt>
<dd>are taking a monoamine oxidase inhibitor (MAOI) medicine.  Ask your doctor or pharmacist if you are not sure.</dd>
<dt>•</dt>
<dd>are taking reserpine.<span class="Bold">  Do not take medicines that contain reserpine (such as Serpalan<span class="Sup">®</span> and Renese<span class="Sup">®</span>-R) with tetrabenazine tablets.  If your doctor plans to switch you from taking reserpine to tetrabenazine tablets, you must wait at least 20 days after your last dose of reserpine before you start taking tetrabenazine tablets.</span>
</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking tetrabenazine tablets?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions, including if you: </span></p>
<dl>
<dt>•</dt>
<dd>have emotional or mental problems (for example, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, previous suicidal thoughts or <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>)</dd>
<dt>•</dt>
<dd>have liver disease</dd>
<dt>•</dt>
<dd>have any allergies. See the end of this Medication Guide for a complete list of the ingredients in tetrabenazine tablets.</dd>
<dt>•</dt>
<dd>have breast cancer or a history of breast cancer</dd>
<dt>•</dt>
<dd>have heart disease that is not stable, have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or recently had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></dd>
<dt>•</dt>
<dd>have an irregular heart beat (<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>)</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant.  It is not known if tetrabenazine tablets can harm your unborn baby.</dd>
<dt>•</dt>
<dd>are breast-feeding.  It is not known if tetrabenazine tablets passes into breast milk.</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription medicines and nonprescription medicines, vitamins and herbal products.  Using tetrabenazine tablets with certain other medicines may cause serious side effects<span class="Bold">.  Do not start <span class="Underline">any</span> new medicines while taking tetrabenazine tablets without talking to your doctor first. </span></p>
<p><span class="Bold">How should I take tetrabenazine tablets?</span></p>
<dl>
<dt>•</dt>
<dd>Tetrabenazine is a tablet that you take by mouth.</dd>
<dt>•</dt>
<dd><span class="Bold">Take tetrabenazine tablets exactly as prescribed by your doctor.  </span></dd>
<dt>•</dt>
<dd>You may take tetrabenazine tablets with or without food. </dd>
<dt>•</dt>
<dd>Your doctor will increase your dose of tetrabenazine tablets each week for several weeks, until you and your doctor find the best dose for you.</dd>
<dt>•</dt>
<dd>If you stop taking tetrabenazine tablets or miss a dose, your involuntary movements may return or worsen in 12 to 18 hours after the last dose.</dd>
<dt>•</dt>
<dd>Before starting tetrabenazine tablets, you should talk to your healthcare provider about what to do if you miss a dose.  If you miss a dose and it is time for your next dose, do not double the dose. </dd>
<dt>•</dt>
<dd>Tell your doctor if you stop taking tetrabenazine tablets for more than <span class="Bold">5</span> days. <span class="Bold">Do not take another dose until you talk to your doctor. </span>
</dd>
<dt>•</dt>
<dd><span class="Bold">If your doctor thinks you need to take more than 50 mg of tetrabenazine tablets each day, you will need to have a blood test to see if it is safe for you.</span></dd>
</dl>
<p><span class="Bold">What should I avoid while taking tetrabenazine tablets? </span></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span> (sedation) is a common side effect of tetrabenazine tablets.  While taking tetrabenazine tablets, <span class="Bold">do not drive a car or operate dangerous machinery until you know how tetrabenazine tablets affects you.</span> Drinking alcohol and taking other drugs that may also cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> while you are taking tetrabenazine tablets may increase any <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> caused by tetrabenazine tablets.</p>
<p><span class="Bold">What are the possible side effects of tetrabenazine tablets? </span></p>
<p><span class="Bold">Tetrabenazine tablets can cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, suicidal thoughts, or actions. </span>See "What is the most important information I should know about tetrabenazine<span class="Underline"> tablets</span>?"</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS).  </span>Call your doctor right away and go to the nearest emergency room if you develop these signs and symptoms that do not have another obvious cause:<dl>
<dt>•</dt>
<dd> high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>•</dt>
<dd> stiff muscles</dd>
<dt>•</dt>
<dd> problems thinking</dd>
<dt>•</dt>
<dd> very fast or uneven heartbeat</dd>
<dt>•</dt>
<dd> increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>. </span>Symptoms of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> include:  slight <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, body <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, trouble moving or keeping your balance.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>. </span>You may get a condition where you feel a strong urge to move.  This is called <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Trouble swallowing.</span> Tetrabenazine tablets may increase the chance that you will have trouble swallowing.  Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> may be the first sign that you are having trouble swallowing.  Trouble swallowing increases your risk of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Irregular heartbeat. </span>  Tetrabenazine tablets increases your chance of having certain changes in the electrical activity in your heart which can be seen on an electrocardiogram (EKG).  These changes can lead to a dangerous abnormal heartbeat.  Taking tetrabenazine tablets with certain medicines may increase this chance.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> due to blood pressure changes when you change position (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>).  </span>Change positions slowly from lying down to sitting up and from sitting up to standing when taking tetrabenazine tablets.  Tell your doctor right away if you get dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> while taking tetrabenazine tablets. Your doctor may need to watch your blood pressure closely.</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> (TD). </span>TD is a condition where there is repeated facial <span class="product-label-link" type="condition" conceptid="4221082" conceptname="Grimaces">grimacing</span> that cannot be controlled, sticking out of the tongue, smacking of the lips, puckering and pursing of the lips, and rapid eye blinking. Tetrabenazine tablets work like other drugs that can cause TD. If you get TD with tetrabenazine tablets, it is possible that the TD will not go away.</dd>
</dl>
<p><span class="Bold">Common side effects with tetrabenazine tablets include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (sedation)</dd>
<dt>•</dt>
<dd>trouble sleeping</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> (<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
</dl>
<p><span class="Bold">Tell your doctor if you have any side effects. Do not stop taking tetrabenazine tablets without talking to your doctor first. </span></p>
<p><span class="Bold">Call your doctor for medical advice about side effects.  You may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. </span></p>
<p><span class="Bold">General information about tetrabenazine tablets</span></p>
<p>Tetrabenazine tablets contain the active ingredient tetrabenazine.  It also contains these inactive ingredients: lactose, maize starch, talc, and magnesium stearate.  The 25 mg tablet, which is <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, also contains yellow iron oxide.</p>
<p>Medicines are sometimes prescribed for conditions that are not listed in a Medication Guide.  Do not use tetrabenazine tablets for a condition for which it was not prescribed.  Do not give tetrabenazine tablets to other people, even if they have the same symptoms that you have.  It may harm them.  Keep tetrabenazine tablets out of the reach of children.</p>
<p>This Medication Guide summarizes the most important information about tetrabenazine tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about tetrabenazine tablets that is written for healthcare professionals. You can also call <span class="Bold">1-800-321-4576.</span></p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:<br>Oceanside Pharmaceuticals, a division of </p>
<p>Valeant Pharmaceuticals North America LLC</p>
<p>Bridgewater, NJ 08807 USA</p>
<p>By: <br>Recipharm Fontaine SAS<br>Rue des Prés Potets, 21121 Fontaine-les-Dijon,<br>France</p>
<p>Made in France</p>
<p>Rev. 02/2015<br>9443700</p>
<p>607470A</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_29a464e0-cbdb-4cd4-981a-355d17ee61bc"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 12.5 mg Bottle Label</span></p>
<p><span class="Bold">NDC</span> 68682-421-12<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Tetrabenazine Tablets</span></p>
<p><span class="Bold">12.5 mg</span></p>
<p><span class="Bold">OCEANSIDE®</span></p>
<p><span class="Bold">PHARMACEUTICALS</span></p>
<p><span class="Bold">112 Tablets</span><br></p>
<div class="Figure">
<a name="id-2074499965"></a><img alt="Tetrabenazine-12.5mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&amp;name=Tetrabenazine-12.5mg.jpg.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_83b304a2-cf40-443f-9560-763f3b8c6704"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg Bottle Label</span></p>
<p><span class="Bold">NDC</span> 68682-422-25<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">Tetrabenazine Tablets</span></p>
<p><span class="Bold">25 mg</span></p>
<p><span class="Bold">OCEANSIDE®</span></p>
<p><span class="Bold">PHARMACEUTICALS</span></p>
<p><span class="Bold">112 Tablets</span><br></p>
<div class="Figure">
<a name="id618805806"></a><img alt="Tetrabenazine-25mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5867189c-17bd-4e70-a079-c4730f9950d1&amp;name=Tetrabenazine-25mg.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TETRABENAZINE 		
					</strong><br><span class="contentTableReg">tetrabenazine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68682-421</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TETRABENAZINE</strong> (TETRABENAZINE) </td>
<td class="formItem">TETRABENAZINE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biplanar) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CL;12;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68682-421-12</td>
<td class="formItem">112  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021894</td>
<td class="formItem">07/20/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TETRABENAZINE 		
					</strong><br><span class="contentTableReg">tetrabenazine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68682-422</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TETRABENAZINE</strong> (TETRABENAZINE) </td>
<td class="formItem">TETRABENAZINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (yellowish-buff) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biplanar) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CL;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68682-422-25</td>
<td class="formItem">112  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021894</td>
<td class="formItem">07/20/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Oceanside Pharmaceuticals
							(832011691)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Recipharm Fontaine SAS</td>
<td class="formItem"></td>
<td class="formItem">260428962</td>
<td class="formItem">MANUFACTURE(68682-421, 68682-422)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a00c16af-38c8-4b66-bdb7-3bde4b6de41c</div>
<div>Set id: 5867189c-17bd-4e70-a079-c4730f9950d1</div>
<div>Version: 2</div>
<div>Effective Time: 20150201</div>
</div>
</div> <div class="DistributorName">Oceanside Pharmaceuticals</div></p>
</body></html>
